Next, we found that the tiplaxtinin/gemcitabine/anti-PD1 treatment led to a reduction in the number of tumor M2 macrophage infiltration as shown by the reduced number of macrophages coexpressing F4/80 and Arg1 (F4/80+/Arg1+) compared to the placebo treatment (Fig. 6, I and J, and fig. The gene discussed is PDCD1; the disease is neoplasm.